INVIMA device registration: original-language biocompatibility and sterilization files with a Spanish summary

I keep getting the same invoice from device teams filing in Colombia: a line for hundreds of pages of biocompatibility tables, sterilization validation logs and risk-analysis annexes, all translated into Spanish at a per-word rate, then a second invoice when INVIMA asks a clarifying question about a number that drifted in translation. The first invoice was optional. The second one was not.

I'm Julio Martinez-Clark. I co-founded Amavita Sciences™ after years of putting device dossiers in front of Latin American regulators with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. This piece is about one Colombia-specific rule that most commodity translation shops ignore: under INVIMA Circular 1298 de 2013, certain deep technical verification documents may be filed in the original language with a Spanish executive summary. That is not a loophole. It is written guidance from INVIMA's Dirección de Dispositivos Médicos. Using it correctly cuts cost and calendar without weakening the file. Using it wrong still gets you an observation.

Colombia's medical device registration regime sits in Decreto 4725 de 2005. That decree is the backbone. Circular 1298 de 2013 is the operational clarification from INVIMA's Dirección de Dispositivos Médicos on how language works for a defined set of technical documents.

Under Article 49 and Article 18 literales d, e, j and k of Decreto 4725, Circular 1298 states that documents covering, among others, biocompatibility, sterility, stability, risk analysis, clinical studies and test reports may be submitted in the original language with a Spanish summary. The summary is not optional window dressing. It must contain at least three elements: a description, the methodology, and the results or conclusions.

Read that list carefully. It maps to the annexes that usually inflate a translation quote: ISO 10993 biocompatibility reports, ISO 14971 risk management files, ISO 11135 or ISO 11137 sterilization validation packages, stability protocols and laboratory test reports. Those are exactly the files where commodity agencies bill for every cell of every table. Circular 1298 tells you that INVIMA will accept the original-language source plus a Spanish resumen that covers description, methodology and results. That is a different scope of work than translating 300-plus pages of raw appendices.

What Circular 1298 does not say is that every technical document can stay in English. Labels and inserts remain patient- and user-facing. Those still need Spanish. So do instructions for use, surgical technique guides, primary and secondary labeling, and clinical evaluation summaries that a reviewer or clinician will read as the operative text. The Circular carves out specific verification categories. It does not rewrite the labeling rule.

The trap is easy to fall into because it looks diligent. A regulatory manager asks a translation vendor for a "complete Spanish dossier." The vendor quotes per word. The biocompatibility appendix alone may run hundreds of pages of cytotoxicity tables, extractables data, residual analysis and raw instrument logs. The sterilization validation may add another stack of cycle printouts and bioburden worksheets. The risk file adds FMEA rows. The quote looks large, the timeline stretches three to four weeks, and everyone feels the file is "safer" because more Spanish exists.

Two things go wrong.

First, engineering data does not survive casual localization. Decimal separators flip. Units get "helpfully" converted on one page and left alone on another. A residual ethylene oxide value, a SAL claim, or a cytotoxicity grade drifts between the Spanish table and the original lab report. A reviewer who checks the numbers against the source then has a discrepancy that did not exist in the English file. You paid to create a problem.

Second, you spent money and calendar on pages Circular 1298 does not require you to translate in full. In operator terms, that redundant technical translation routinely sits in the $10,000 to $25,000 range and burns three to four weeks on the critical path. Those are planning ranges from programs I have seen, not a quote and not a promise. The point is the order of magnitude: enough to matter on a Colombia launch plan, and avoidable when you scope the file against Circular 1298 instead of against a per-word invoice.

I do not quote per-word rates in this article, and I will not. Per-word pricing is the wrong unit for regulatory verification annexes. The right unit is: which documents need a certified Spanish resumen, which need full sworn or certified Spanish text, and which stay in the original language with the summary attached.

Circular 1298 is not a reason to under-translate the dossier. It is a reason to put translation where the reviewer and the patient actually need it.

Keep full Spanish (and the right certification tier) for:

• Instructions for use and patient or user information that travel with the device.
• Surgical technique guides and operator manuals that clinicians will follow.
• Primary and secondary labeling, including the mandatory content Colombia expects on the pack.
• Clinical evaluation summaries and other narrative documents a reviewer will treat as the operative clinical story.
• Legal instruments (powers of attorney, distributor authorizations, certificates of free sale) that need sworn or authenticated Spanish translation under the applicable rule.

For the Circular 1298 categories — biocompatibility under ISO 10993, risk analysis under ISO 14971, sterilization validation under ISO 11135 or ISO 11137, stability, clinical studies and test reports among others — plan original-language submission plus a Spanish executive summary that covers description, methodology and results or conclusions. Write that resumen so a reviewer can understand what was done and what was found without re-reading every raw table. Attach the original report. Do not invent article numbers beyond Decreto 4725 Articles 49 and 18 literales d, e, j and k as cited in Circular 1298.

If your regulatory counsel or local representative prefers a fuller Spanish technical file for a specific device class or a specific reviewer history, that is a judgment call. Document the decision. Do not default into full appendix translation because the vendor's template assumes it.

Treat translation scoping as a gate on the registration plan, not a purchase order after the technical file is "done."

1. Inventory the annexes. List every biocompatibility, risk, sterilization, stability, clinical and test report that will sit behind the Colombia registration. Tag each with its source standard (ISO 10993, ISO 14971, ISO 11135, ISO 11137, or other).
2. Map each document to Circular 1298 or to labeling. If it falls under the Circular's verification categories, the default plan is original language plus Spanish resumen (description, methodology, results/conclusions). If it is patient- or user-facing, it needs full Spanish.
3. Write the resumen from the report, not from a marketing brief. The summary has to track the actual methods and results. A vague paragraph that says "biocompatibility was evaluated per ISO 10993" without methodology and conclusions fails the Circular's minimum content.
4. Protect numbers. Whatever stays in the original language still has to match the Spanish documents that surround it: device name, intended use, residual limits, sterilization claims. Terminology consistency across the dossier is still the gate that stops first-cycle observations.
5. Certify at the right tier. Technical IFUs and manuals normally need certified technical translation. Legal instruments often need sworn translation and authentication. Do not over-certify raw lab appendices you are not fully translating, and do not under-certify labels and IFUs.

Amavita Sciences™ runs device files through a six-step pipeline — Upload, Localization, Medical Review, Regulatory QA, Export Package, Submission Ready — described on our platform page. For a Colombia INVIMA file, Regulatory QA is where Circular 1298 scoping either holds or gets corrected before money is spent on pages that do not need full Spanish. The goal is first-pass acceptance on language grounds: remove translation as a reason for INVIMA to stop the clock, without pretending that approval itself is a language promise.

First-pass acceptance, in this context, means INVIMA does not bounce the file because the biocompatibility annex was left in English without a proper Spanish resumen, or because a commodity Spanish table no longer matches the lab report, or because labels still carry English-only patient instructions. It does not mean automatic registration. Classification, technical evidence and the rest of Decreto 4725 still govern.

A clean Colombia translation plan usually looks like this:

• Original-language ISO 10993 package with a Spanish resumen that states what was tested, how, and what the conclusions were.
• Original-language ISO 14971 risk file with a Spanish resumen of the risk process and residual-risk conclusions.
• Original-language sterilization validation (ISO 11135 or ISO 11137 as applicable) with a Spanish resumen of the method, cycle parameters and sterility assurance conclusions.
• Full Spanish IFU, surgical technique guide and labeling, checked against Colombia's labeling expectations and against the same term list used in the summaries.
• Legal documents at the certification tier the filing requires.

That plan is shorter and cheaper than translating every appendix cell, and it is closer to what Circular 1298 actually authorizes. Teams that skip the resumen and file English-only verification reports create a different failure mode. Teams that translate everything create cost and inconsistency. The middle path is the one the Circular describes.

Colombia is not Peru, Uruguay or the Dominican Republic. DIGEMID, MSP and DIGEMAPS each shape the Spanish file differently, which is why we published a separate note on why one Spanish dossier does not fit those three markets. Circular 1298 is Colombia-specific. Do not export its original-language-plus-summary rule to a country that has not written the same guidance.

What does travel across the region is the discipline behind first-review acceptance: one term list, intact numbers, country-correct labels, and the right certification tier. That framework is laid out in our piece on first-review acceptance for Latin American device translation files. Colombia adds a useful cost lever inside that framework: stop paying for full Spanish on annexes Circular 1298 lets you keep in the original language.

Our free LATAM regulatory translation matrix cites the instrument behind each language rule for twelve regulators, including INVIMA. Use it to decide where Colombia's Circular 1298 carve-out applies and where full Spanish still governs.

If you are preparing an INVIMA registration and your current plan assumes every biocompatibility, risk and sterilization page will be translated into Spanish, stop and re-scope against Circular 1298 before you issue the purchase order. Send us the annex list and the device class. We will return a document-by-document map: original language plus Spanish resumen, full certified Spanish, or sworn Spanish, tied to Decreto 4725 and Circular 1298, and run through the six-step pipeline toward a submission-ready export package.

You can start a LATAM pilot here, or begin from our medical device translation services page. If the clinical side of the same program also runs in Latin America, bioaccess® runs first-in-human device studies in the region, and the same terminology base can carry from the trial file into the Colombia registration file.

Julio Martinez-Clark, co-founder, Amavita Sciences™, and CEO, bioaccess®. Operator guidance only; not legal advice. Confirm current requirements with INVIMA and your local representative before filing. Cost and timeline figures above are operator planning ranges, not quotes.